Mycophenolate Mofetil Hexal (Mycophenolate Mofetil)

Mycophenolate Mofetil is employed in immunosuppressive regimens targeting organ transplantation and autoimmune kidney disease.

• Kidney transplant rejection: reduces the risk of acute and chronic graft rejection.
• Heart transplant rejection: helps maintain cardiac graft function by suppressing lymphocyte activity.
• Lupus nephritis: controls renal inflammation and slows disease progression.

• Mycophenolate Mofetil selectively inhibits inosine monophosphate dehydrogenase, an enzyme essential for de novo guanine nucleotide synthesis. By limiting guanine availability, the drug impairs proliferation of T and B lymphocytes, which rely heavily on this pathway, thereby providing targeted immunosuppression without broadly affecting other cell types.

Mycophenolate Mofetil may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Nausea: mild to moderate upset stomach.
• Diarrhea: loose stools that may be watery.
• Headache: occasional throbbing pain.
• Tremor: fine shaking of hands or limbs.
• Abdominal pain: cramping or discomfort.
• Infections: increased susceptibility to common bacterial or viral infections.

Serious or Rare Side Effects

• Leukopenia: significant drop in white blood cells.
• Anemia: reduced red blood cell count leading to fatigue.
• Severe infections: opportunistic infections such as Pneumocystis jirovecii pneumonia.
• Hepatic toxicity: elevated liver enzymes or hepatitis.
• Malignancy: increased risk of certain cancers with long‑term use.
• Progressive multifocal leukoencephalopathy (PML): rare but life‑threatening brain infection.

When prescribing Mycophenolate Mofetil, clinicians should observe several safety precautions.

• Monitor blood counts: perform regular complete blood count tests to detect leukopenia or anemia.
• Assess renal function: adjust therapy based on creatinine clearance and kidney status.
• Evaluate liver enzymes: check hepatic function periodically.
• Avoid live vaccines: live attenuated vaccines can cause infection under immunosuppression.
• Use effective contraception: teratogenic risk requires reliable birth control for both sexes.
• Store at below 25°C: keep in the original packaging, protect from moisture and heat.

Mycophenolate Mofetil interacts with several medicines that can alter its efficacy or safety.

Major Interactions (Avoid)

• Azathioprine: combined use markedly increases bone marrow suppression.
• Cyclosporine or tacrolimus: may raise mycophenolic acid levels, increasing toxicity risk.
• Cholestyramine or other bile‑acid sequestrants: reduce absorption of mycophenolate.

Moderate Interactions (Monitor Closely)

• Antacids containing magnesium or aluminum: may modestly decrease drug bioavailability.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.
• Non‑live vaccines: immunogenicity may be reduced; timing should be coordinated with the treating physician.